More than 34,000 bottles of Nostrilla nasal decongestant have been pulled from the market because they may have bacterial contamination.
The Nostrilla recall was announced on October 19, by the FDA and the manufacturers, Insight Pharmaceuticals, after internal investigations discovered excessive amounts of the bacteria Burkholderia cepacia. There have been no illnesses reported in connection with the contaminated nasal decongestant.
The recall affects one lot of Nostrilla Nasal Decongestant consisting of 34,092 1/2 ounce plastic bottles. The bottles will be labeled with lot # 11G075 and an expiration date of 05/2014 stamped on the side. The bottles were distributed nationwide in pharmacies and retail outlets.
The effects of a Burkholderia Cepacia infection may vary widely. While some individuals may exhibit no symptoms at all, others could experience serious respiratory infections. The bacteria has also been known to cause “foot-rot” among soldiers though it is more commonly associated with the development of serious health conditions in individuals with cystic fibrosis (CF) and those with chronic lung disease.
For individuals with existing health problems, Burkholderia Cepacia can attack the lungs and deterioration may be gradual or accelerated depending on the health of the person and on the type of Burkholderia Cepacia. In some cases, the bacteria could lead to pneumonia and death.
The FDA and Insight Pharmaceuticals recommend that any consumers who purchased Nostrilla Nasal Decongestant from the affected lot contact the company at 1-877-546-9059 and return the product.
Anyone who experiences an adverse reaction should contact their physician or healthcare provider. The FDA requests that any adverse reactions also be reported to the FDA’s MedWatch adverse event reporting program.